<DOC>
	<DOCNO>NCT01568762</DOCNO>
	<brief_summary>This study design compare safety , tolerability , pharmacokinetics QBX258 ( sequential administration fix dose VAK694 single ascending dos QAX576 ) patient well-controlled mild moderate asthma .</brief_summary>
	<brief_title>To Compare Safety , Tolerability , Pharmacokinetics QBX258 Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female subject age 1860 year ( inclusive ) Well control mild moderate atopic asthma Female subject must postmenopausal surgically sterile Male subject must use two method contraception Subjects must positive skin prick test one common airborne allergen Participation clinical investigation use investigational drug time enrollment A history clinically significant ECG abnormality History malignancy organ system Smokers ( use tobacco product previous 3 month ) Use prescription drug require control relief asthma Use oral steroid within 12 week prior dose FEVI &lt; 80 % predict screen baseline Use albuterol twice week relief asthma Patients suffer active hay fever baseline likely require treatment study History chronic respiratory disease asthma chronic allergic rhinitis Emergency room visit within 6 week screen due asthma Hospitalization asthma last year History intubation/assisted ventilation asthma last 5 year Administration live vaccine within precede month Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>VAK694</keyword>
	<keyword>QAX576</keyword>
	<keyword>QBX258</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>